Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$0.55 - $0.82 $1,100 - $1,640
2,001 Added 53.73%
5,725 $4,000
Q1 2023

May 15, 2023

BUY
$0.65 - $1.37 $509 - $1,074
784 Added 26.67%
3,724 $2,000
Q4 2022

Feb 14, 2023

SELL
$0.6 - $1.41 $6,610 - $15,533
-11,017 Reduced 78.94%
2,940 $2,000
Q3 2022

Nov 14, 2022

SELL
$0.94 - $2.56 $16,797 - $45,747
-17,870 Reduced 56.15%
13,957 $14,000
Q2 2022

Oct 27, 2022

BUY
$1.78 - $5.02 $22,915 - $64,627
12,874 Added 67.93%
31,827 $60,000
Q2 2022

Aug 15, 2022

BUY
$1.78 - $5.02 $22,915 - $64,627
12,874 Added 67.93%
31,827 $60,000
Q1 2022

Oct 27, 2022

SELL
$3.54 - $8.08 $45,573 - $104,021
-12,874 Reduced 40.45%
18,953 $94,000
Q1 2022

May 13, 2022

BUY
$3.54 - $8.08 $21,693 - $49,514
6,128 Added 47.78%
18,953 $94,000
Q4 2021

Feb 14, 2022

SELL
$5.69 - $7.83 $346,731 - $477,136
-60,937 Reduced 82.61%
12,825 $97,000
Q3 2021

Nov 15, 2021

BUY
$7.88 - $14.0 $581,244 - $1.03 Million
73,762 New
73,762 $583,000

Others Institutions Holding HARP

About Harpoon Therapeutics, Inc.


  • Ticker HARP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,106,800
  • Description
  • Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candi...
More about HARP
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.